Status:
COMPLETED
Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.
Lead Sponsor:
AstraZeneca
Conditions:
Endometrial Carcinoma
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the efficacy of a monthly administration of Fulvestrant in patients with recurrent or metastatic endometrial carcinoma by assessment of the clinical tumour re...
Eligibility Criteria
Inclusion
- Histologically confirmed, recurrent or metastatic endometrial carcinoma
- Postmenopausal
- Hormonreceptor positive
Exclusion
- Pre-treatment with Fulvestrant
- Previous endocrine therapy of the endometrial carcinoma
- Previous malignancy less than 3 years ago other than in situ carcinoma of the cervix, basal cell carcinoma or squamous carcinoma of the skin
Key Trial Info
Start Date :
December 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00334295
Start Date
December 1 2002
End Date
January 1 2011
Last Update
July 31 2012
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Erlangen, Germany
2
Research Site
Göttingen, Germany
3
Research Site
Halle, Germany
4
Research Site
Jena, Germany